{"id":186403,"date":"2026-03-30T00:00:00","date_gmt":"2026-03-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/47037426-medtech-varicose-vein-treatment-devices-market-insights\/"},"modified":"2026-04-22T23:01:28","modified_gmt":"2026-04-22T23:01:28","slug":"48000633-medtech-varicose-vein-treatment-devices-market-insights-united-states","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/48000633-medtech-varicose-vein-treatment-devices-market-insights-united-states\/","title":{"rendered":"Varicose Vein Treatment Devices &#8211; Market Insights &#8211; United States"},"content":{"rendered":"<p>The US varicose vein treatment device market will be driven by the continued shift toward minimally invasive procedures and the evolving reimbursement landscape supporting endovenous ablation and sclerotherapy technologies. These modalities have increasingly become the preferred firstline options over surgical stripping due to favorable safety profiles, strong clinical outcomes, and the expansion of officebased treatment settings.<\/p>\n<p>This Medtech 360 Report provides comprehensive data and analysis on the state of the market for\u00a0varicose vein treatment devices in the US from 2019 through 2034.<\/p>\n<div><strong>Competitor dynamics are shifting in the varicose vein treatment device market.<\/strong><\/div>\n<p>How will competitive dynamics among endovenous ablation, phlebectomy, and sclerotherapy evolve as adoption of minimally invasive treatments increases?<\/p>\n<p>What is the market outlook for Varithena, the only available readytouse microfoam?<\/p>\n<p class=\"question-statement\"><strong>Nonthermal technologies are emerging.<\/strong><\/p>\n<p><!--%3Cmeta%20content%3D%22text%2Fhtml%3B%20charset%3Dus-ascii%22%20http-equiv%3D%22Content-Type%22%3E--><\/p>\n<p>How will emerging nonthermal, nontumescent devices, including innovations like Basis Medical\u2019s Seclusion catheter, influence adoption patterns and competitive positioning?<\/p>\n<p>How will established thermal ablation options (<abbr title=\"Endovenous Laser Ablation\">ELA<\/abbr> and <abbr title=\"Endovenous Radiofrequency Ablation\">ERFA<\/abbr>) compete against new nonthermal modalities as reimbursement and siteofservice dynamics evolve?<\/p>\n<div>\n<div>Will price pressure, reprocessing dynamics, and outpatient siteofservice preferences reinforce or weaken the position of thermal ablation over time?<\/div>\n<\/div>\n","protected":false},"template":"","class_list":["post-186403","report","type-report","status-publish","hentry","report-gateway-medtech","medtech-therapy-area-cardiovascular","medtech-therapy-area-varicose-vein-treatment-devices","medtech-geography-united-states","medtech-date-2828"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/186403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/186403\/revisions"}],"predecessor-version":[{"id":577769,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/186403\/revisions\/577769"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=186403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}